Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
6 evidence topics · 4 sources
Medications excluded before randomization in the phase 3 trial
Required vaccination against encapsulated bacteria in the phase 3 trial
Medications excluded before randomization in the phase 2 trial
Required meningococcal vaccination in the phase 2 trial
Background immunosuppressive therapy at baseline in the phase 2 trial
| Characteristic | Placebo (N=22) | Claseprubart 300 mg every 2 weeks (N=21) | Claseprubart 600 mg every 2 weeks (N=22) |
|---|---|---|---|
| Baseline corticosteroid use, n (%) | “19 (86%)” | “17 (81%)” | “20 (91%)” |
| Number of immunosuppressive therapies at baseline: 1, n (%) | “11 (50%)” | “10 (48%)” | “12 (55%)” |
| Number of immunosuppressive therapies at baseline: more than 1, n (%) | “11 (50%)” | “11 (52%)” | “10 (45%)” |
| Neonatal Fc receptor blocker use in prior 24 months, n (%) | “0 (0%)” | “1 (5%)” | “0 (0%)” |
| Prior complement inhibitor use, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |
| Prior thymectomy, n (%) | “8 (36%)” | “6 (29%)” | “7 (32%)” |